Tag Archives: IBS-D

NICE in the United Kingdom Gives Positive Recommendation for Eluxadoline (Truberzi) for IBS-D

Today, via the social media of the IBS Network, the U.K. charity for irritable bowel syndrome, IBS Impact received the following linked press release from Allergan, the pharmaceutical company for eluxadoline, which is known in the U.K. and throughout the European Union by the brand name Truberzi. This is the same medication which is known …

Continue reading

U.S. Food and Drug Administration Issues Drug Safety Communication for IBS-D Medication Eluxadoline (Viberzi), March 2017

Today, March 15, 2017, IBS Impact learned via IFFGD social media that the U.S. Food and Drug Administration (FDA) issued a drug safety communication for eluxadoline (also known by the brand name Viberzi), currently used in treating irritable bowel syndrome with diarrhea in adults, 18 and older, both men and women. This warning applies specifically …

Continue reading

U.S. Food and Drug Administration Approves Eluxadoline and Rifaximin for IBS with Diarrhea

Earlier this week, on May 27, 2015, the U.S. Food and Drug Administration approved two new medications, eluxadoline (to be known by the brand name Viberzi) and rifaximin (known by the brand name Xifaxan)  for use in treating irritable bowel syndrome with diarrhea in adults, 18 and older, both men and women. Both medications have …

Continue reading

Clinical Trial: Mesalazine for Irritable Bowel Syndrome with Diarrhea (IBS-D), United Kingdom

The Nottingham University Hospitals Trust, King’s Mill Hospital Mansfield, Derby Royal Hospital and Wythenshawe Hospital Manchester are looking for men and women age 18-75 with Rome III criteria diarrhea-predominant IBS to participate in a clinical trial of the medication mesalazine for the treatment of IBS. Other eligibility requirements or exclusions may apply.  Mesalazine is a common, established treatment for inflammatory bowel disease …

Continue reading

Clinical Trial: Lexicon Pharmaceuticals Investigational Medication for IBS-D

UPDATE: As of November 2012, there is an additional dedicated site to inquire about participating in this study at http://www.ibsdstudy.com Thank you to Western States Clinical Research for this updated information.  This study is posted at the request of Western States Clinical Research, Inc. in Wheat Ridge, Colorado, one of many participating study sites throughout the U.S. This Phase …

Continue reading

Clinical Trial: Furiex Pharmaceuticals Investigational Medication for IBS-D

The details of this study were obtained from the websites of IFFGD,  Furiex Pharmaceuticals and Clinical Trials.gov (52 week trial, 26 week trial) Furiex Pharmaceuticals is currently recruiting volunteers “to evaluate the effectiveness, safety, and tolerability of JNJ-27018966 (the Investigational drug) compared with an inactive placebo in patients with irritable bowel syndrome (IBS) with the …

Continue reading